Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update
NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. (“Varian Bio”), a private, precision oncology company developing novel...
Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.
Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor...
SPK Acquisition Corp. Announces that Common Stock and Rights to Commence Separate Trading on or about July 23, 2021
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- SPK Acquisition Corp. ("the Company" or "SPK") (NASDAQ: SPKAU), a blank check company formed for the purpose of entering into a merger, share exchange, asset...